Trials / Completed
CompletedNCT07240051
Efficacy of Different Types of Chemical Peels in the Treatment of Acne Vulgaris
Assessment of the Efficacy and Safety of 50% Glycolic Acid, 30% Salicylic Acid, and Modified Jessner's Chemical Peels in the Treatment of Active Acne and Post-acne Hyperpigmentation: Randomized Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Nahla Maher Mahmoud Mahran · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Accepted
Summary
Assessment of the Efficacy and Safety of 50% Glycolic Acid, 30% Salicylic Acid, and Modified Jessner's Chemical Peels in the Treatment of Active Acne and Post-acne Hyperpigmentation: Randomized Controlled Trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Glycolic acid peel alone | Using a cotton tip applicator, a single coat of commercially prepared 50% GA peeling agent was evenly applied to the patient's face. Neutralization of the peel was done on reaching uniform erythema (endpoint) within 3-5 minutes. If frosting was observed in any area before the set time or endpoint, the area was neutralized with sodium bicarbonate |
| PROCEDURE | salicylic acid | Using a cotton tip applicator, a single coat of commercially prepared 30% SA peeling agent was evenly applied to the patient's face, moving from the forehead and advancing to the cheeks, chin, glabella, nose, and perioral area. Once white crystallization appeared, patients were asked to wash their faces with water. |
| PROCEDURE | modified jessener | Commercially prepared MJ peel was applied using a gauze piece and light hand pressure. A single coat of peel was uniformly applied over the entire face. The coat was allowed to dry completely until erythema or frosting occurred, at which point patients were asked to wash their faces with cold water. |
Timeline
- Start date
- 2024-03-09
- Primary completion
- 2024-06-10
- Completion
- 2024-07-12
- First posted
- 2025-11-20
- Last updated
- 2025-11-20
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07240051. Inclusion in this directory is not an endorsement.